Tevogen Bio Inc

Contributing Author

Recent Articles by Tevogen Bio Inc

Sep-10	Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston TVGN GlobeNewswire
Sep-09	Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection TVGN GlobeNewswire
Sep-08	Tevogen Values TVGN-489 at $9-$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell Allogeneic T Cell Platform TVGN GlobeNewswire
Sep-04	Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas TVGN GlobeNewswire
Sep-03	Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2 TVGN GlobeNewswire
Aug-27	Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure TVGN GlobeNewswire
Aug-26	Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity TVGN GlobeNewswire
Aug-25	Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions TVGN GlobeNewswire
Aug-22	Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma TVGN GlobeNewswire
Aug-19	REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts TVGN GlobeNewswire
Aug-19	Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum TVGN GlobeNewswire
Aug-18	Tevogen CEO Donates Personal Shares to Support Local Law Enforcement TVGN GlobeNewswire
Aug-18	Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery TVGN GlobeNewswire
Aug-14	Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected TVGN GlobeNewswire
Aug-13	Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell Model With a Focus on Oncology TVGN GlobeNewswire
Aug-11	Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion TVGN GlobeNewswire
Aug-11	REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion TVGN GlobeNewswire
Aug-11	Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow TVGN GlobeNewswire
Aug-11	REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders TVGN GlobeNewswire
Aug-08	REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions TVGN GlobeNewswire
Aug-07	Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy TVGN GlobeNewswire
Aug-06	Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions TVGN GlobeNewswire
Aug-05	Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell Model With a Focus on Oncology TVGN GlobeNewswire
Aug-01	Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders TVGN GlobeNewswire
Aug-01	Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion TVGN GlobeNewswire
Jul-30	Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision TVGN GlobeNewswire
Jul-28	Tevogen.AI Applauds U.S. Government's AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare TVGN GlobeNewswire
Jul-18	Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides TVGN GlobeNewswire
Jul-17	Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility TVGN GlobeNewswire
Jul-16	Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell Alpha Launch TVGN GlobeNewswire
Jul-14	Tevogen.AI Builds Alpha Version of PredicTcell Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs TVGN GlobeNewswire
Jul-10	Tevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation TVGN GlobeNewswire
Jun-30	Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters TVGN GlobeNewswire
Jun-18	Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery TVGN GlobeNewswire
Jun-09	Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives TVGN GlobeNewswire
May-30	Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships TVGN GlobeNewswire
May-23	Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow TVGN GlobeNewswire
May-22	Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting TVGN GlobeNewswire
May-12	Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation TVGN GlobeNewswire
May-02	Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest TVGN GlobeNewswire

Tevogen Bio Inc

Recent Articles by Tevogen Bio Inc

Upgrade your FINVIZ experience